{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:05:07Z","timestamp":1769551507199,"version":"3.49.0"},"reference-count":48,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"Shriners Hospitals for Children, Cincinnati"},{"name":"University of Cincinnati Start-up Grant"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Development and Technology"],"published-print":{"date-parts":[[2022,2,7]]},"DOI":"10.1080\/10837450.2022.2038201","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T12:07:50Z","timestamp":1644235670000},"page":"242-250","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Pirfenidone as a potential antifibrotic injectable for Dupuytren\u2019s disease"],"prefix":"10.1080","volume":"27","author":[{"given":"Suchitra","family":"Panigrahi","sequence":"first","affiliation":[{"name":"James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Barry","sequence":"additional","affiliation":[{"name":"Research Department, Shriners Hospitals for Children-Cincinnati, Cincinnati, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Multner","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald B.","family":"Kasting","sequence":"additional","affiliation":[{"name":"James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio A. Landero","family":"Figueroa","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latha","family":"Satish","sequence":"additional","affiliation":[{"name":"Research Department, Shriners Hospitals for Children-Cincinnati, Cincinnati, OH, USA"},{"name":"Department of Pathology & Laboratory Medicine, University of Cincinnati, Cincinnati, OH, USA"},{"name":"Division of Asthma Research, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshita","family":"Kumari","sequence":"additional","affiliation":[{"name":"James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,2,20]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1097\/SAP.0b013e31821b6d08"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1097\/01.bth.0000186794.90431.a4"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0363-5023(96)80102-X"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-016-1200-y"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1308\/003588406X83104"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.math.2015.01.010"},{"key":"CIT0007","unstructured":"[CDER] Center for Drug Evaluation and Research (U.S.) and [CBER] Center for Biologics Evaluation and Research (U.S.). 2003. Guidance for industry Q1A(R2) stability testing of new drug substances and products. Rockville (MD): U.S. Dept. of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research. http:\/\/purl.access.gpo.gov\/GPO\/LPS113798."},{"key":"CIT0008","unstructured":"CFDEA Research. 2017. Pharmacology\/toxicology NDA review and evaluation. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209819Orig1s000PharmR.pdf"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/S0363-5023(78)80112-9"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903501539"},{"key":"CIT0011","unstructured":"[CHMP] Committee for Human Medicinal Products. 2017. Benzyl alcohol and benzoic acid group used as excipients."},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-017-1713-z"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1177\/1753193412467170"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-018-1030-3"},{"issue":"59","key":"CIT0015","first-page":"PA3695","volume":"46","author":"Duck A","year":"2015","journal-title":"Eur Respir J"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1053\/jssh.2003.50005"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810866"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1177\/106002809603000703"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.0c00237"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.2174\/1874325001105010283"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1208\/pt060471"},{"key":"CIT0022","doi-asserted-by":"crossref","unstructured":"Hindocha S, McGrouther DA, Bayat A. 2009. Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology. Los Angeles (CA): SAGE Publications; p. 256\u2013269.","DOI":"10.1007\/s11552-008-9160-9"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.06.022"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0041-3"},{"key":"CIT0025","unstructured":"National Center for Biotechnology Information. PubChem compound summary for CID 40632 Pirfenidone.\u00a0[Accessed March 3, 2019]. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Pirfenidone"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.4055\/cios.2019.11.3.332"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1177\/1753193414528843"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1097\/00006534-199405000-00018"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.4772.1328"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.2106\/00004623-197658030-00016"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0510-4"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-008-9050-z"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02396-8"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.07.016"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00001111"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1097\/01.prs.0000278455.63546.03"},{"key":"CIT1037","doi-asserted-by":"crossref","unstructured":"Strickley RG. 2004. Solubilizing excipients in oral and injectable formulations. Pharma res. 21(2):201\u2013230.","DOI":"10.1023\/B:PHAM.0000016235.32639.23"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2014.10.023"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2005.pto_97108.x"},{"key":"CIT0039","unstructured":"U.S. Food and Drug Administration. 2014a. Chemistry review, NDA 22-535 Esbriet Pirfenidone capsules."},{"key":"CIT0040","unstructured":"U.S. Food and Drug Administration. 2014b. Esbriet (pirfenidone) capsules: US prescribing information."},{"key":"CIT0041","unstructured":"U.S. Food and Drug Administration. Inactive ingredient database for approved drug products.\u00a0[Accessed March 2019]. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/iig\/index.Cfm"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01101-6"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e31823aea95"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1006\/excr.2000.4869"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.05.069"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-016-1326-y"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-019-2486-3"}],"container-title":["Pharmaceutical Development and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10837450.2022.2038201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T16:39:13Z","timestamp":1651077553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10837450.2022.2038201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,7]]}},"alternative-id":["10.1080\/10837450.2022.2038201"],"URL":"https:\/\/doi.org\/10.1080\/10837450.2022.2038201","relation":{},"ISSN":["1083-7450","1097-9867"],"issn-type":[{"value":"1083-7450","type":"print"},{"value":"1097-9867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iphd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iphd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}